Survival advantage opens personalized route for Apogenix's glioblastoma therapy
This article was originally published in Scrip
Executive Summary
Apogenix's glioblastoma treatment APG101 can increase overall survival in patients positive for a biomarker associated with the drug's target, new analyses of its Phase II study have shown. The data make it the first product in many years to prolong life in this notoriously difficult to treat disease, and encourage the company to hope that it may become the new standard of care in this disease.